Open access peer-reviewed chapter - ONLINE FIRST

Artemisinin: A Revolutionary Antimalarial Agent

Written By

Mohan Tiwari and Saman Pathan

Submitted: 26 February 2025 Reviewed: 07 April 2025 Published: 17 June 2025

DOI: 10.5772/intechopen.1010440

Breaking the Cycle of Malaria - Molecular Innovations, Diagnostics, and Integrated Control Strategies IntechOpen
Breaking the Cycle of Malaria - Molecular Innovations, Diagnostic... Edited by Yash Gupta

From the Edited Volume

Breaking the Cycle of Malaria - Molecular Innovations, Diagnostics, and Integrated Control Strategies [Working Title]

Dr. Yash Gupta, Dr. Surendra Kumar Prajapati and Dr. Raja Babu Kushwah

Chapter metrics overview

9 Chapter Downloads

View Full Metrics

Abstract

The treatment of malaria has significantly improved with the groundbreaking antimalarial drug artemisinin, which is derived from Artemisia annua. It was found in the 1970s and damages Plasmodium parasites by producing reactive oxygen species. Because of its quick action and effectiveness against drug-resistant strains, artemisinin-based combination treatments (ACTs) are the gold standard. However, long-term efficacy is threatened by resistance, particularly in Southeast Asia. The history, mechanism, and clinical application of artemisinin are examined in this chapter, along with its function in the prevention of malaria and current studies aimed at overcoming resistance and creating novel derivatives. In the worldwide battle against malaria, artemisinin is still essential.

Keywords

  • artemisinin
  • malaria
  • Plasmodium
  • ACTs
  • resistance
  • Artemisia annua
  • therapeutic innovations

1. Introduction

In the fight against malaria, artemisinin and its derivatives are an essential and potent class of medications. Extensive worldwide study has improved our knowledge of this extraordinary phytochemical, including its distinct chemical and pharmacological characteristics, since its discovery in the early 1970s.

Today, while artemisinin remains the cornerstone of antimalarial therapy, several challenges have emerged in its ongoing use and development. These include the rise of delayed treatment responses to artemisinin in malaria patients and attempts to repurpose these drugs for non-malaria applications.

A crippling illness that has affected people all over the world since ancient times, malaria remains one of the most pervasive, destructive, and deadly epidemics in human history [1]. Malaria, which frequently emerged and spread in the humid regions surrounding marshes and swamps, was once thought to be caused by the “bad air” preventing it in these areas [2]. This misconception gave rise to the term “malaria”, derived from the medieval Italian words ma (bad) and aria (air). For centuries, the disease was wrongly attributed to foul air, delaying the discovery of its true transmissible and parasitic nature. It was not until the late 1800s that the groundbreaking discoveries of Charles Louis Alphonse Laveran and Roland Ross uncovered the true cause of malaria. Their discoveries revealed that malaria is caused by protozoa of the Plasmodium genus and is primarily transmitted by Anopheles mosquitoes. These groundbreaking findings earned Laveran and Ross recognition as among the earliest recipients of the Nobel Prize in Physiology or Medicine [3].

Only five of the more than 100 Plasmodium species can affect humans. The main causes of malaria are Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, and the extremely deadly Plasmodium falciparum, but Plasmodium knowlesi is not very dangerous to people.

Malaria treatment depends on chemotherapy with medication that targets various stages of the Plasmodium parasite’s life cycle. These consist of mefloquine (Larium), lumefantrine, doxycycline, quinoline compounds, sulfadoxine/pyrimethamine, and artemisinin-based combination treatment (ACTs). Mefloquine (ASMQ), lumefantrine (Coatem), amodiaquine (ASAQ), piperaquine (Duo-Cotecxin), pyronaridine (Pyramax), and other antimalarial medications are often combined with an artemisinin derivative in the most widely used ACTs. Additionally, preventative medicines like chloroquine, doxycycline, mefloquine (Lariam), primaquine, and the atovaquone-proguanil combination (Malarone) may be used for prophylaxis when necessary [4].

The World Health Organization (WHO) started the Emergency Response to Artemisinin Resistance in the Greater Mekong Subregion and the Global Plan for Artemisinin Resistance Containment (GPARC) to combat the growing threat of artemisinin-tolerant and resistant malaria. These programs support a systemic, multi-tiered strategy aimed at preventing, reducing, and eventually eradicating the emergence and transmission of malaria that is resistant to artemisinin [5]. Significantly lowering the worldwide malaria burden has been made possible by increasing access to artemisinin-based combination treatments (ACTs) in areas where malaria is endemic. At present, no alternative antimalarial treatment matches the efficacy and tolerability of ACTs.

Advertisement

2. Artemisinin

A naturally occurring sesquiterpene lactone substance with a distinct chemical structure is artemisinin, and its derivatives, which are collectively referred to as ‘artemisinin’ unless otherwise noted. It comes from the Asteraceae family’s sweet wormwood plant (Artemisia annua L.). Artemisinin has been proven effective against different forms of Plasmodium parasites, making it a focal point of significant scientific and medical interest [6, 7]. The discovery of artemisinin traces back to a Chinese government initiative in the late 1960s aimed at finding a cure for malaria. Tu Youyou won the 2015 Nobel Prize in Physiology or Medicine for her revolutionary discovery in 1972, which was the result of her hard work. The current global standard for treating malaria caused by Plasmodium falciparum and other Plasmodium species is artemisinin-based combination treatments (ACTs).

Since the 1980s, artemisinin derivatives have increasingly become the focus of research due to their affordability, effectiveness, and ease of use [8, 9, 10]. In 2006, the World Health Organization (WHO) officially recommended artemisinin-based combination therapies (ACTs) as the first-line treatment for Plasmodium falciparum malaria [11, 12]. Artemisinin and its derivatives remain the most crucial and effective drugs for malaria treatment [13]. However, the emergence of drug-resistant Plasmodium falciparum has driven continuous advancements in antimalarial drug research, with particular focus on enhancing artemisinin-based combination therapies (ACTs) [13, 14, 15].

Advertisement

3. Chemical structure of artemisinin and its derivatives

Artemisinin is a sesquiterpene trioxane lactone distinguished by the presence of a unique peroxide bridge (-O-O-) within a seven-membered ring; when its peroxide bridge interacts with iron in the parasite, leading to the destruction of the parasite’s cellular structure, which is crucial for its antimalarial activity (Figure 1) [16]. The lactone group in artemisinin can be readily reduced using sodium borohydride, yielding dihydroartemisinin. This derivative demonstrates even greater antimalarial activity in vitro compared to artemisinin itself [17].

Figure 1.

Artemisinin.

To enhance its effectiveness, numerous derivatives (Figures 26) have been synthesized from dihydroartemisinin. Among them, artemether, arteether, artesunate, and artelinic acid are either currently in use or under evaluation. These derivatives play a crucial role in artemisinin-based combination therapies (ACTs), which the WHO recommends as the first-line treatment for Plasmodium falciparum malaria [18].

  1. Dihydroartemisinin (DHA): It is a semisynthetic derivative or a reduced form of artemisinin where the lactone is converted to a hydroxy group. Known for enhanced solubility in water and greater antimalarial potency compared to artemisinin. It kills parasites by damaging their membranes and disrupting their mitochondrial function. DHA is low in toxicity and has saved many lives [19].

  2. Artemether: A peroxide-containing lactone, a derivative of dihydroartemisinin formed by methylation of the hydroxy group. Lipophilic, making it suitable for intramuscular injection or oral use. It is used to treat uncomplicated malaria.

  3. Arteether: Arteether is an ethyl ether derivative of dihydroartemisinin. Its lipophilic nature allows for intramuscular administration in long-acting formulations. Being oil soluble, it has an extended elimination half-life (greater than 20 hours), enhanced chemical stability, and greater overall stability compared to other artemisinin compounds [20].

  4. Artesunate: A water-soluble derivative of dihydroartemisinin achieved through hemisuccinate esterification. Commonly used in severe malaria cases due to its rapid action and intravenous or intramuscular administration.

  5. Artelinic acid: It is a semisynthetic derivative of artemisinin, specifically a triaxone dicarboxylic acid derivative of dihydroartemisinin (DHA). It was developed to improve the pharmacokinetic properties and stability of artemisinin derivatives for antimalarial therapy. Artelinic acid retains the core sesquiterpene trioxane lactone structure of artemisinin but introduces a dicarboxylic acid group, which enhances its water solubility and chemical stability compared to other derivatives like artesunate. The peroxide bridge (-O-O-) critical for antimalarial activity is preserved.

Figure 2.

Dihydroartemisinin (DHA).

Figure 3.

Artemether.

Figure 4.

Arteether.

Figure 5.

Artesunate.

Figure 6.

Artelinic acid.

Each of these derivatives retains the critical peroxide bridge, which is activated upon interaction with iron from the parasite’s heme, generating free radicals that inflict damage on the parasite. These structural modifications enhance solubility, bioavailability, and pharmacokinetics, optimizing the derivatives for specific clinical applications.

Advertisement

4. Extraction of artemisinin

In 1969, Professor Youyou Tu was appointed to lead a research team as part of a project dedicated to screening Traditional Chinese Medicine (TCM) for novel antimalarial drugs. The China Academy of Chinese Medical Sciences’ Institute of Chinese Materia Medica is where this study was carried out. A list of more than 2000 herbal medicines was developed by Tu and her team using a wealth of TCM knowledge, including folklore, ancient literature, and practitioner interviews. They then reduced this list to about 640 viable options. From this refined selection, they tested more than 380 extracts from around 200 herbs, including Qinghao (Artemisia annua), though most failed to produce satisfactory results [21, 22]. The Qinghao extract, however, gained significant attention around 1971 due to its promising yet inconsistent results. This inconsistency prompted a meticulous re-examination of the traditional literature, ultimately leading to a pivotal breakthrough in the discovery process.

Drawing from classical literature, particularly Ge Hong’s Zhouhou Beiji Fang (Handbook of Prescriptions for Emergency), and her deep knowledge of Traditional Chinese Medicine (TCM), Tu proposed a crucial modification to the extraction process using low-temperature conditions to preserve the active compounds. The extracts obtained through this refined method were further purified by separating the acidic and neutral phases, a technique designed to retain the active components while reducing toxicity. This strategy produced a breakthrough: in tests carried out in or around October 1971, the resultant material demonstrated 100% efficacy against rodent malaria. In late December of the same year, this astounding discovery was confirmed in full in monkey malaria trials, conclusively demonstrating the effectiveness of the Qinghao extract [21].

This success confirmed the safety profile of the Qinghao extract, allowing clinical trials to proceed without delay in the latter half of 1972. The extract’s effectiveness in treating malaria was further confirmed by the extremely positive outcomes of the studies, which were carried out in Hainan Province and at the 302 Hospital PLA (now a component of the fifth Medical Center of the Chinese PLA General Hospital) in Beijing. These results helped propel Qinghao's research to the national level, driving further investigation and development. A concerted effort by the Chinese scientific community further propelled the research and development of Qinghao. In November 1972, Tu’s team at the Institute of Chinese Materia Medica successfully isolated the active component from the Qinghao extract; artemisinin (also known as Qinghaosu).building on this discovery the team later developed dihydroartemisinin (DHA), a derivative that remains one of the most pharmacologically significant antimalarial agents in use today.

Subsequently, artemisinin-based therapies significantly improved parasite clearance and quickly reduced symptoms in both mild and severe Plasmodium falciparum malaria infections, particularly when paired with slower-acting antimalarials like mefloquine or piperaquine. Additionally, these treatments demonstrated excellent tolerability with minimal reports of toxicity or safety concerns [22].

The exceptional effectiveness and safety of artemisinin-based treatments became more evident after more than 10 years of independent randomized clinical trials and meta-analyses. In 2006, the WHO officially revised its treatment guidelines to fully implement artemisinin-based combination therapies (ACTs) as the first-line treatment for malaria [23]. To this day, ACTs remain the most effective and widely recommended antimalarial treatments [24].

Advertisement

5. Biosynthesis of artemisinin

Two C5 isoprenoid units from the cytosolic mevalonate (MVA) pathway and one isoprenoid unit from the non-mevalonate (MEP or DXP) pathway [25] are used to manufacture Farnesyl pyrophosphate (FPP, C15), a crucial precursor of artemisinin [19, 20, 26]. FPP then undergoes cyclization through the enzymatic action of amorpha-4,11-diene synthase (ADS), leading to the formation of amorpha-4,11-diene [27, 28, 29]. This process involves the generation of bisabolyl and 4-amorphenyl cation intermediates (Figure 7) [25, 30, 31].

Figure 7.

Biosynthesis of artemisinin. Source: Ref. [25]. [updated 2025 Apr 03]. Available from: https://link.springer.com/article/10.1007/s11418-016-1008-y CC BY 4.0.

Amorpha-4,11-diene 12-monooxygenase (CYP71AV1) then oxidizes amorpha-4,11-diene to artemisinin alcohol [32]. Additionally, this enzyme makes it easier for artemisinic alcohol to continue oxidizing into artemisinic aldehyde and subsequently artemisinic acid. Additionally, alcohol dehydrogenase 1 (ADH1) catalyzes the oxidation of artemisinic alcohol to artemisinic aldehyde, while aldehyde dehydrogenase 1 (ALDH1) converts artemisinic aldehyde into artemisinic acid [33, 34]. Initially, artemisinic acid was thought to be the final precursor of artemisinin [25]. However, studies have revealed that it undergoes non-enzymatic conversion into arteannuin B and related compounds rather than directly forming artemisinin [25, 35].

Artemisinic aldehyde Δ11(13) reductase (DBR2) catalyzes the reduction of artemisinic aldehyde to dihydroartemisinic aldehyde [25], which is the subsequent stage in the production of artemisinin [36]. As shown in Figure 7, aldehyde dehydrogenase 1 (ALDH1) subsequently oxidizes dihydroartemisinic aldehyde to dihydroartemisinic acid, which subsequently goes through a non-enzymatic conversion to artemisinin [33, 36]. The enzyme dihydroartemisinic aldehyde reductase 1 (RED1), which converts dihydroartemisinic aldehyde to dihydroartemisinic alcohol, was discovered by Rydén et al. [37]. Although the exact function of RED1 in the biosynthesis of artemisinin is yet unknown, research indicates that Artemisia annua may produce more artemisinin if RED1 is silenced.

Artemisinin is primarily synthesized in glandular secretory trichomes (GSTs), and as the plant ages, its accumulation decreases. According to Olofsson et al. [38], Artemisia anna has GSTs in all aerial tissues but not in roots or hairy roots. The highest density of GSTs is seen in flower buds and young leaves, progressive decreasing as the leaves age [25].

Advertisement

6. Antimalarial mechanism of artemisinin/mechanism of action of artemisinin

Artemisinin and its derivatives exhibit potent and rapid antimalarial activity by reducing malaria parasite levels and alleviating symptoms. They act by disrupting the erythrocytic stage of the parasite’s life cycle, particularly inhibiting merozoite formation in red blood cells. The activation of artemisinin relies on the cleavage of its endoperoxide bridge, leading to the generation of reactive free radical species. Two primary activation pathways have been proposed: the mitochondrial pathway and the heme-mediated degradation pathway [39, 40].

6.1 Bioactivation of artemisinin in parasite

A number of protease enzymes in the malaria parasite’s host break down hemoglobin, releasing peptides and amino acids necessary for the parasite’s growth and freeing up room in the digesting vacuole. Hematine accumulates during this process, which can be quite harmful to the parasite, as shown in Figure 8 [42]. To mitigate this threat, the parasite has developed a detoxification mechanism wherein hematin undergoes biomineralization, forming insoluble and non-toxic hemozoin, commonly referred to as malaria pigment.

Figure 8.

Detoxification of hemoglobin. Source: Ref. [41]. [updated 2025 Apr 03]. Available from: https://pubmed.ncbi.nlm.nih.gov/20336009/ CC BY 4.0.

Detoxification of hemoglobin: The malaria parasite transforms toxic hematin, which is created when heme monomers hydrogen bond [42], into hemozoin, an insoluble, non-toxic substance. Recent studies suggest that during hemozoin formation, the propionate group of each Fe(III) PPIX molecule coordinates with the Fe(III) center of an adjacent molecule, stabilizing the crystalline structure and reducing toxicity [43].

6.2 Mitochondria-activated artemisinin

It induces cytotoxicity by triggering lipid peroxidation, generating reactive oxygen species (ROS), and causing depolarization of the parasite’s mitochondrial and plasma membranes [40, 44, 45, 46, 47]. Superoxide anion, hydroxyl radical, peroxy radical, hydrogen peroxide, and lipid hydroperoxide are examples of radical or pro-radical compounds that contain oxygen. These highly reactive molecules inhibit malaria parasite survival by damaging critical biomolecules, such as lipids, proteins, and nucleic acids, ultimately disrupting cellular integrity and function [47]. Reducing iron from the unstable iron pool in the cytoplasm of Plasmodium, along with iron released from heme decomposition, activates artemisinin to generate free radicals, which play a crucial role in its antimalarial action. Two primary types of free radicals contribute to this effect: oxygen free radicals and carbon free radicals. However, their formation is sequential rather than simultaneous. Under the influence of iron, the peroxy bridge in artemisinin is cleaved, leading to the production of oxygen-free radicals, which subsequently facilitate the formation of carbon-free radicals through electron rearrangement [48].

6.3 Heme-mediated pathway

In the heme-mediated activation pathway, two models have been proposed: the reductive scission model and the open peroxide model, both of which lead to the formation of an active carbon-centered radical [41, 49]. Additionally, while some studies suggest that heme plays a major role in artemisinin activation, outweighing the contribution of Fe2+ ions, despite some studies suggesting that non-heme Fe2+ ions can bind to and activate artemisinin [50, 51]. As shown in Figure 9, heme is generated in Plasmodium species by hemoglobin breakdown at the trophozoite stage and endogenous production during the early ring stage. However, the amount of heme produced by hemoglobin digestion is much greater than that produced by endogenous heme, indicating that hemoglobin-derived heme plays a dominating role in artemisinin activation [51, 53].

Figure 9.

Antimalarial mechanism of artemisinin. Source: Ref. [52]. [updated 2025 Apr 03]. Available from: https://www.mdpi.com/2414-6366/9/9/223# CC By 4.0.

Hemozoin, a parasite pigment, is deposited within the food vacuole following hemoglobin digestion. Although the plasmodium stages are most vulnerable to artemisinin action, which happens too early in development to show visible pigment, despite the fact that it has long been suggested that artemisinins target it [54, 55]. In infected erythrocytes, excess heme is converted into hematin, a toxic molecule capable of inducing oxidative damage and lysing cell membranes [56]. To neutralize hematin toxicity, malarial parasites employ a detoxification mechanism that converts hematin into inert, crystallized hemozoin through a biocrystallization process [43]. Activated artemisinin has been reported to inhibit hemozoin formation by alkylating heme, functioning similarly to other antimalarial drugs that target hemozoin synthesis, such as chloroquine (CQ) [57, 58, 59, 60]. Consequently, free heme from hemoglobin digestion serves as both the activator and target of artemisinin, reinforcing its potent antimalarial effect [57].

In in vitro studies, the endoperoxide bridge of artemisinin is proposed to be activated by ferrous iron, generating oxygen- or carbon-centered free radicals, which subsequently alkylate heme. Since iron is a key component of hemozoin, the digestion of hemoglobin by the parasite is believed to make them particularly vulnerable to locally activated artemisinins. Heme and iron produced by hemozoin can activate artemisinin to produce free radicals. The activated artemisinin disrupts the physiological functions of Plasmodium by targeting proteins, lipids, and nucleic acids, leading to the parasites’ death. The asterisk signifies the activated form of ART.

6.4 The intra-erythrocytic parasite and proposed targets of artemisinins

Plasmodiun falciparum replicates within red blood cells, relying on hemoglobin digestion for survival during its 48-hour asexual life cycle (Figure 10) [61]. Artemisinin have long been proposed to target the parasite’s hemoglobin digestion process within the ‘food vacuole’ (Figure 10b). Additionally, studies suggest that artemisinins may also act on the parasite mitochondrion, the translationally controlled tumor protein (TCTP), and PfATP6, parasite-encoded sarcoplasmic-endoplasmic reticulum calcium ATPase (SERCA).

Figure 10.

Complex life cycle of Plasmodium falciparum. Source: Krishna et al. [61] [Updated 2025 Apr 03]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2758403/ CC BY 3.0. DV, digestive vacuole; ER, endoplasmic reticulum; AA for amino acids; Ap for apicoplast; ART for artemisinins; G, the Golgi apparatus; M stands for mitochondria; N for the nucleus; Hb for hemoglobin; Hz for hemoglobin; Red blood cells, or RBCs; translationally controlled tumor proteins, or TCTPs.

The intricate life cycles of parasites that cause human malaria involve three cycles of asexual reproduction and one cycle of sexual reproduction, and they depend on both human hosts and mosquito vectors. Within the host’s red blood cells, one of the asexual stages takes place (Figure 10a). Invasive forms of the parasite, known as merozoites, enter red blood cells and remain relatively metabolically inactive for 10–15 hours during the ring stage. This is followed by a rapid growth phase over the next 25 hours, forming the trophozoite stage, during which the parasite digests most of the host cell’s hemoglobin and expands to occupy more than 50% of the cell’s volume. Hemoglobin digestion occurs within a specialized organelle called the food vacuole (Figure 10b), leading to the formation of heme. As heme is generated, it associates through one of its peripheral carboxyl groups with the Fe3+ of an adjacent heme molecule, forming insoluble hemozoin. It has been suggested that a protein called histidine-rich protein II aids in this process, albeit this has not been proved. The parasite goes through several rounds of division during the schizont stage after the trophozoite stage. The cycle is continued when the host cell lyses 48 hours after invasion, releasing freshly produced merozoites.

Over the years, it has been suggested that artemisinins target a variety of pathways, some of which may not require activation by Fe2+ (Figure 10b). These include the endoplasmic reticulum-localized calcium pump known as PfATP6, the mitochondrion, the translational controlled tumor protein (TCTP), and the heme detoxification route.

Advertisement

7. Artemisinin resistance

Clinically, artemisinin resistance is characterized by the delayed clearance of malaria parasites from the bloodstream following treatment with artemisinin derivatives or artemisinin-based combination therapies (ACTs) [62]. The delayed clearance of malaria parasites following artemisinin treatment is more precisely termed “partial resistance”, as it is restricted to specific timeframes and stages within the parasite’s life cycle. Research indicates that resistance mechanisms predominantly impact the ring stage, allowing parasites to temporarily withstand drug exposure before progressing through later developmental stages [63]. The emergence of partial artemisinin resistance is worrisome, as it could progressively extend to other stages of the parasite’s life cycle. If this evolution continues, it may ultimately result in complete resistance, compromising the efficacy of artemisinin-based treatments.

To mitigate the risk of artemisinin resistance, it is essential to use a potent partner drug in artemisinin-based combination therapies (ACTs). Furthermore, careful evaluation of the ACT partner drug’s efficacy is necessary to minimize the likelihood of treatment failure [49, 50]. Resistance to ACT partner drugs has been detected in the Greater Mekong Subregion (GMS) [51]. Effective management of drug resistance necessitates continuous monitoring of the efficacy of both artemisinins and their partner drugs, alongside a thorough investigation of the underlying resistance mechanisms. Mutations in the K13 gene, along with alterations in other associated genes, have been identified as key contributors to the emergence of artemisinin resistance in Plasmodium parasites (Figure 11).

Figure 11.

The mechanism of artemisinin resistance. Source: Ref. [52]. [updated 2025 Apr 03]. Available from: https://www.mdpi.com/2414-6366/9/9/223# CC By 4.0.

The PfK13 mutation decreases the endocytosis of host hemoglobin, which lowers hemoglobin catabolism levels and inhibits the activation of artemisinin medications. Furthermore, the K13 mutation improves DNA repair processes and reduces protein damage, increasing resistance to artemisinin. Other mutations, including Pfcoronin, AP-2μ, and UBP1, may further inhibit artemisinin activation, thereby reducing its parasiticidal effect.

Advertisement

8. Therapeutic properties of artemisinin and its derivatives

Ongoing research has led to the widespread clinical adoption of artemisinin compounds, extending their use beyond malaria treatment. These compounds have shown promising potential in treating other parasitic diseases, as well as in combating tumors, inflammation, and various other medical conditions [64, 65, 66, 67].

8.1 Anti-schistosomiasis effect

Artemisinin and its derivatives can deplete cellular iron and selectively target iron-dependent cells [68, 69]. Artemisinin compounds have been shown to effectively kill both malaria ring-stage parasites and schistosomula, independent of hemozoin formation. This suggests that both Plasmodium parasites and schistosomes rely on iron for survival. Additionally, studies indicate that parasitized erythrocytes contain higher iron levels than uninfected red blood cells, further supporting the role of iron in the action of artemisinins [70]. Furthermore, iron levels increase as the malaria parasite progresses from the early ring stage to the late schizont stage [70]. Artemisinin and its derivatives exhibit anti-schistosomiasis effects by inducing oxidative stress within the schistosome parasite, leading to cellular damage and death. This effect primarily occurs through interactions with iron within the parasite’s body. Clinical studies have shown that ACTs can specifically reduce transmission and contribute to the elimination of schistosomiasis [71]. Additionally, their use in treating both urinary schistosomiasis [72] and intestinal schistosomiasis [73] has been found to be safe and effective.

8.2 Anti-toxoplasma gondii effect

Toxoplasma gondii can be effectively killed by nanomolar concentrations of artemisone in in vitro models. It is a sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) orthologue, TgSERCA, which shares similarities with PfATP6 in Plasmodium and has been shown to be susceptible to inhibition by artemisinin when expressed in yeast [74]. Additionally, artemisinins interfere with calcium metabolism in parasites, disrupting their invasion mechanisms. The extent of these effects may vary depending on whether the parasites are residing within host cells or exist as free-living organisms [75].

8.3 Activity against pathogenic picomplexan parasites

Babesia species are tick-borne intra-erythrocytic parasites capable of infecting humans and various domestic animals, depending on the specific parasite species. Unlike Plasmodium infections, Babesia does not form a parasitophorous vacuole and does not digest hemoglobin to produce hemozoin [76]. These studies further confirm that neither hemozoin nor hemoglobin is essential for the antiparasitic activity of artemisinins. This raises interest in evaluating the SERCA hypothesis as a potential mechanism of action of artemisinins in these related pathogenic parasites.

8.4 Antitumour properties of artemisinins

Artemisinins, particularly artesunate, have exhibited potent activity against various tumor cell lines, including those associated with colon, breast, and lung cancer, as well as leukemia and pancreatic cancer [77, 78]. Artemisinins inhibit human umbilical vein endothelial cells’ (HUVECs’) migration, proliferation, and tube formation. Furthermore, they suppress the production of VEGF receptors and prevent vascular endothelial growth factor (VEGF) from attaching to surface receptors on HUVECs. KDR/flk-1 and Flt-1 [79, 80]. In cancer cells, artemisinins downregulate the VEGF receptor KDR/flk-1 in both tumor and endothelial cells, leading to the inhibition of angiogenesis and tumor progression. This effect has been demonstrated in studies where artemisinins slowed the growth of human ovarian cancer HO-8910 xenografts in nude mice [80, 81].

8.5 Cardioprotective effect of artemisinins

Preclinical studies have shown that artemisinin and its derivatives hold promising potential for treating various diseases, including cardiovascular diseases (CVDs) [80]. In vitro studies, conducted in a controlled environment outside the physiological system, help elucidate the precise molecular mechanisms by which these compounds act on target cells. Artemisinin and its derivatives have demonstrated the ability to attenuate CVD progression by targeting specific cellular components.

Advertisement

9. Conclusions

Adequate knowledge and further research on the biological activities of Artemisia annua, particularly its key constituents such as artemisinin and other crucial metabolites, will provide deeper insights into their therapeutic applications and potential medical benefits. Alongside improved diagnostics and effective vector control measures, artemisinin-based combination therapies (ACTs) have the potential to significantly reduce the burden of malaria in tropical regions. However, to maximize their impact, it is crucial to ensure greater affordability and accessibility. Despite its widespread use, the precise antimalarial mechanism of artemisinin and its derivatives remains unclear, creating challenges for drug development, clinical applications, and malaria control efforts. Further research is crucial to fully understand how artemisinin exerts its effects against malaria. Notably, artemisinin has shown superior antimalarial efficacy compared to many other plant-derived secondary metabolites, highlighting its unique pharmacological properties. Furthermore, extensive research has revealed the potential of artemisinin and its derivatives in managing metabolic disorders and obesity-related diseases. Beyond their well-established antimalarial effects, these compounds exhibit diverse biological activities, including anti-proliferative, anti-angiogenic, antifungal, anti-helminthic, anti-protozoal, anti-tumor, and antibacterial properties. Their broad therapeutic potential continues to drive interest in their application across various medical fields. Key derivatives of artemisinin, including dihydroartemisinin (DHA), artesunate, artemisone, artemisinin, artemiside, artemether, and arteether, have all been identified in Artemisia annua. Future research should prioritize the development of novel pharmaceutical formulations incorporating targeted transport systems. These advancements could enhance the anticancer efficacy of artemisinin and its derivatives, opening new avenues for therapeutic applications and treatment strategies across various medical fields.

Advertisement

Acknowledgments

SP wants to thank MT for the concept of the content. Both the authors are grateful to IntechOpen and Dr. Yash Gupta for giving us the opportunity.

Conflict of interest

The authors declare no conflict of interest.

Abbreviations

HMD-CoA 3

hydroxy-3-methylglutaryl-coenzyme A

G3P

glycerol-3-phosphate

DXP

1-deoxy-D-xylulose 5-phosphate

MEP

2C-methyl-D-erythritol 4-phosphate

CDP-ME

4-diphosphocytidyl-2C-methyl D-erythritol

CDP-MEP

CDP-ME 2-phosphate

MEC-PP

2C-methyl-D-erythritol 2,4-cyclodiphosphate

HMB-PP

(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate

IPP

isopentenyl pyrophosphate

DMAPP

dimethylallyl pyrophosphate

atoB

(ERG10) acetoacetyl-CoA thiolase

HMGS

(ERG13) HMG-CoA synthase

HMGR

HMG-CoA reductase

MK

(EGR12) mevalonate kinase

PMK

(ERG8) phosphomevalonate kinase

MVD1

(ERG19) mevalonate pyrophosphate decarboxylase

dxs

DXP synthase

dxr

DXP reductase

ispD

CDP-ME synthase

ispE

CDP-ME kinase

ispF

MEC-PP synthase

ispG

HMB-PP synthase

ispH

HMB-PP reductase

IDI

IPP isomerase

FPS (ispA)

farnesyl pyrophosphate (FPP) synthase

SQS

(ERG9) squalene synthase

ADS

amorpha-4,11-diene synthase

CYP71AV1

amorpha-4,11-diene 12-monooxygenase

CPR

cytochrome P450 reductase

ADH1

alcohol dehydrogenase 1

ALDH1

aldehyde dehydrogenase 1

DBR2

artemisinic aldehyde Δ11(13) reductase

RED1

dihydroartemisinic aldehyde reductase 1

ART

artemisinin

Hb

hemoglobin

Pfcoronin

Plasmodium falciparum actin-binding protein coronin

AP-2μ

adaptor protein 2μ

UBP1

upstream binding protein 1

References

  1. 1. Wang J, Xu C, Wong YK, Li Y, Liao F, Jiang T, et al. Artemisinin, the magic drug discovered from traditional Chinese medicine. Engineering. 2019;5(1):32-39. DOI: 10.1016/j.eng.2018.11.011
  2. 2. Hempelmann E, Krafts K. Bad air, amulets and mosquitoes: 2,000 years of changing perspectives on malaria. Malaria Journal. 2013;12:1-4. DOI: 10.1186/1475-2875-12-232
  3. 3. Cox FE. History of the discovery of the malaria parasites and their vectors. Parasites and Vectors. 2010;3:5. DOI: 10.1186/1756-3305-3-5
  4. 4. Centers for Disease Control and Prevention. Choosing a drug to prevent malaria. 2015. Available from: http://www.cdc.gov/malaria/travelers/drugs.html [Accessed: November 18, 2018]
  5. 5. World Health Organization. Global Plan for Artemisinin Resistance Containment (GPARC). World Health Organization; 2011. Available from: http:/www.who.int/malaria/publications/atoz/9789241500’838
  6. 6. Badshah SL, Ullah A, Ahmad N, Almarhoon ZM, Mabkhot Y. Increasing the strength and production of artemisinin and its derivatives. Molecules. 2018;23(1):100. DOI: 10.3390/molecules23010100
  7. 7. Talman AM, Clain J, Duval R, Ménard R, Ariey F. Artemisinin bioactivity and resistance in malaria parasites. Trends in Parasitology. 2019;35(12):953-963
  8. 8. Shi C, Li H, Yang Y, Hou L. Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives. Mediators of Inflammation. 2015;2015(1):435713. DOI: 10.1155/2015/435713
  9. 9. Wang JG, Zhu XX. Advances in the study of artemisinin targets and mechanisms in chemical biology. Kexue Tongbao (Chinese science bulletin) (Chin Ed). 2017;62(18):1973-1981
  10. 10. Guo HQ, Liu SZ, Wang L, Liu ZY, Wang ZH. Research progress of artemisinin and its derivatives against coccidiosis of chicken. Poultry Science. 2020;4:52-56
  11. 11. Isba R, Zani B, Gathu M, Sinclair D. Cochrane infectious diseases group. artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database of Systematic Reviews. 1996;2015(2):1-41. DOI: 10.1002/14651858.CD011547
  12. 12. Naing C, Whittaker MA, Mak JW, Aung K. A systematic review of the efficacy of a single dose artemisinin–naphthoquine in treating uncomplicated malaria. Malaria Journal. 2015;14:1-1. DOI: 10.1186/s12936-015-0919-5
  13. 13. World Health Organization. Global Malaria Programme (GMP), World malaria report 2022. WHO; 2022
  14. 14. Garcia LS. Malaria. Clinics in Laboratory Medicine. 2010;30(1):93-129
  15. 15. Ward KE, Fidock DA, Bridgford JL. Plasmodium falciparum resistance to artemisinin-based combination therapies. Current Opinion in Microbiology. 2022;69:102193. DOI: 10.1016/j.mib.2022.102193
  16. 16. China Cooperative Research Group. On qinghaosu and its derivatives as anti-malarials. Journal of Traditional Chinese Medicine. 1982;2:3-8
  17. 17. Van Agtmael MA, Eggelte TA, Van Boxtel CJ. Artemisinin drugs in the treatment of malaria: From medicinal herb to registered medication. Trends in Pharmacological Sciences. 1999;20(5):199-205
  18. 18. Balint GA. Artemisinin and its derivatives: An important new class of antimalarial agents. Pharmacology & Therapeutics. 2001;90(2-3):261-265. DOI: 10.1016/S0163-7258(01)00140-1
  19. 19. Schramek N, Wang H, Römisch-Margl W, Keil B, Radykewicz T, Winzenhörlein B, et al. Artemisinin biosynthesis in growing plants of Artemisia annua. A 13CO2 study. Phytochemistry. 2010;71(2-3):179-187. DOI: 10.1016/j.phytochem.2009.10.015
  20. 20. Bouwmeester HJ, Wallaart TE, Janssen MH, van Loo B, Jansen BJ, Posthumus MA, et al. Amorpha-4, 11-diene synthase catalyses the first probable step in artemisinin biosynthesis. Phytochemistry. 1999;52(5):843-854. DOI: 10.1016/S0031-9422(99)00206-X
  21. 21. Liao F. Discovery of artemisinin (Qinghaosu). Molecules. 2009;14(12):5362-5366. DOI: 10.3390/molecules14125362
  22. 22. Efferth T, Kaina B. Toxicity of the antimalarial artemisinin and its dervatives. Critical Reviews in Toxicology. 2010;40(5):405-421. DOI: 10.3109/10408441003610571
  23. 23. Olumese P. Guidelines for the Treatment of Malaria. World Health Organization (WHO); 2006
  24. 24. World Health Organization. Global report on insecticide resistance in malaria vectors: 2010-2016. 2018. Available from: https://iris.who.int/handle/10665/272533
  25. 25. Muangphrom P, Seki H, Fukushima EO, Muranaka T. Artemisinin-based antimalarial research: Application of biotechnology to the production of artemisinin, its mode of action, and the mechanism of resistance of plasmodium parasites. Journal of Natural Medicines. 2016;70:318-334
  26. 26. Towler MJ, Weathers PJ. Evidence of artemisinin production from IPP stemming from both the mevalonate and the nonmevalonate pathways. Plant Cell Reports. 2007;26:2129-2136. DOI: 10.1007/s00299-007-0420-x
  27. 27. Chang YJ, Song SH, Park SH, Kim SU. Amorpha-4, 11-diene synthase of Artemisia annua: cDNA isolation and bacterial expression of a terpene synthase involved in artemisinin biosynthesis. Archives of Biochemistry and Biophysics. 2000;383(2):178-184. DOI: 10.1006/abbi.2000.2061
  28. 28. Mercke P, Bengtsson M, Bouwmeester HJ, Posthumus MA, Brodelius PE. Molecular cloning, expression, and characterization of amorpha-4, 11-diene synthase, a key enzyme of artemisinin biosynthesis in Artemisia annua L. Archives of Biochemistry and Biophysics. 2000;381(2):173-180. DOI: 10.1006/abbi.2000.1962
  29. 29. Kim SH, Heo K, Chang YJ, Park SH, Rhee SK, Kim SU. Cyclization mechanism of amorpha-4, 11-diene synthase, a key enzyme in artemisinin biosynthesis. Journal of Natural Products. 2006;69(5):758-762. DOI: 10.1021/np050356u
  30. 30. Picaud S, Mercke P, He X, Sterner O, Brodelius M, Cane DE, et al. Amorpha-4, 11-diene synthase: Mechanism and stereochemistry of the enzymatic cyclization of farnesyl diphosphate. Archives of Biochemistry and Biophysics. 2006;448(1-2):150-155. DOI: 10.1016/j.abb.2005.07.015
  31. 31. Teoh KH, Polichuk DR, Reed DW, Nowak G, Covello PS. Artemisia annua L. (Asteraceae) trichome-specific cDNAs reveal CYP71AV1, a cytochrome P450 with a key role in the biosynthesis of the antimalarial sesquiterpene lactone artemisinin. FEBS Letters. 2006;580(5):1411-1416. DOI: 10.1016/j.febslet.2006.01.065
  32. 32. Polichuk D, Teoh KT, Zhang Y, Ellens KW, Reed DW, Covello PS, et al. Nucleotide sequence encoding an alcohol dehydrogenase from Artemisia annua and uses thereof. United States patent application US 12/737,635. 2011
  33. 33. Teoh KH, Polichuk DR, Reed DW, Covello PS. Molecular cloning of an aldehyde dehydrogenase implicated in artemisinin biosynthesis in Artemisia annua. Botany. 2009;87(6):635-642. DOI: 10.1139/B09-032
  34. 34. Brown GD, Sy LK. In vivo transformations of artemisinic acid in Artemisia annua plants. Tetrahedron. 2007;63(38):9548-9566. DOI: 10.1016/j.tet.2007.06.062
  35. 35. Zhang Y, Teoh KH, Reed DW, Maes L, Goossens A, Olson DJ, et al. The molecular cloning of artemisinic aldehyde Δ11 (13) reductase and its role in glandular trichome-dependent biosynthesis of artemisinin in Artemisia annua. Journal of Biological Chemistry. 2008;283(31):21501-21508. DOI: 10.1074/jbc.M803090200
  36. 36. Brown GD, Sy LK. In vivo transformations of dihydroartemisinic acid in Artemisia annua plants. Tetrahedron. 2004;60(5):1139-1159. DOI: 10.1016/j.tet.2003.11.070
  37. 37. Rydén AM, Ruyter-Spira C, Quax WJ, Osada H, Muranaka T, Kayser O, et al. The molecular cloning of dihydroartemisinic aldehyde reductase and its implication in artemisinin biosynthesis in Artemisia annua. Planta Medica. 2010;76(15):1778-1783. DOI: 10.1055/s-0030-1249930
  38. 38. Olofsson L, Engström A, Lundgren A, Brodelius PE. Relative expression of genes of terpene metabolism in different tissues of Artemisia annua L. BMC Plant Biology. 2011;11:1-2. DOI: 10.1186/1471-2229-11-45
  39. 39. Sun C, Li J, Cao Y, Long G, Zhou B. Two distinct and competitive pathways confer the cellcidal actions of artemisinins. Microbial Cell. 2015;2(1):14. DOI: 10.15698/mic2015.01.181
  40. 40. Pagola S, Stephens PW, Bohle DS, Kosar AD, Madsen SK. The structure of malaria pigment β-haematin. Nature. 2000;404(6775):307-310
  41. 41. O’Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin—The debate continues. Molecules. 2010;15:1705-1721
  42. 42. Egan TJ. Recent advances in understanding the mechanism of hemozoin (malaria pigment) formation. Journal of Inorganic Biochemistry. 2008;102(5-6):1288-1299. DOI: 10.1016/j.jinorgbio.2007.12.004
  43. 43. Wang J, Huang L, Li J, Fan Q, Long Y, Li Y, et al. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One. 2010;5:e9582
  44. 44. Mercer AE, Copple IM, Maggs JL, O’Neill PM, Park BK. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. The Journal of Biological Chemistry. 2011;286:987-996
  45. 45. Hartwig CL, Rosenthal AS, Angelo JD, Griffin CE, Posner GH, Cooper RA. Accumulation of artemisinin trioxane derivatives within neutral lipids of plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochemical Pharmacology. 2009;77:322-336
  46. 46. Antoine T, Fisher N, Amewu R, O’Neill PM, Ward SA, Biagini GA. Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. The Journal of Antimicrobial Chemotherapy. 2014;69:1005-1016
  47. 47. Su L-J, Zhang J-H, Gomez H, Murugan R, Hong X, Xu D, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxidative Medicine and Cellular Longevity. 2019;2019:5080843
  48. 48. Ismail HM, Barton V, Phanchana M, Charoensutthivarakul S, Wong MHL, Hemingway J, et al. Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites plasmodium falciparum 3D7. Proceedings of the National Academy of Sciences of the United States of America. 2016;113:2080-2085
  49. 49. Klonis N, Creek DJ, Tilley L. Iron and heme metabolism in plasmodium falciparum and the mechanism of action of artemisinins. Current Opinion in Microbiology. 2013;16:722-727
  50. 50. Wang J, Zhang CJ, Chia WN, Loh CCY, Li Z, Lee YM, et al. Haem-activated promiscuous targeting of artemisinin in plasmodium falciparum. Nature Communications. 2015;6:10111
  51. 51. Klonis N, Crespo-Ortiz MP, Bottova I, Abu-Bakar N, Kenny S, Rosenthal PJ, et al. Artemisinin activity against plasmodium falciparum required hemoglobin uptake and digestion. Proceedings of the National Academy of Sciences of the United States of America. 2011;108:11405-11410
  52. 52. Zheng D, Liu T, Yu S, Liu Z, Wang J, Wang Y. Antimalarial mechanisms and resistance status of artemisinin and its derivatives. Tropical Medicine and Infectious Disease. 20 Sep 2024;9(9):223
  53. 53. Bray PG. Quinolines and artemisinin: Chemistry, biology and history. Current Topics in Microbiology and Immunology. 2005;295:3-38. DOI: 10.1007/3-540-29088-5_1
  54. 54. Haynes RK. Artemisinin antimalarials do not inhibit hemozoin formation. Antimicrobial Agents and Chemotherapy. 2003;47:1175. DOI: 10.1128/AAC.47.3.1175.2003
  55. 55. Chen G-Q, Benthani FA, Wu J, Liang D, Bian Z-X, Jiang X. Artemisinin compounds sensitize cancer cells to Ferroptosis by regulating iron homeostasis. Cell Death and Differentiation. 2020;27:242-254
  56. 56. Meunier B, Robert A. Heme as trigger and target for trioxane-containing antimalarial drugs. Accounts of Chemical Research. 2010;43(11):1444-1451
  57. 57. Cazelles J, Robert A, Meunier B. Alkylation of heme by artemisinin, an antimalarial drug. Comptes Rendus de l’Académie des Sciences-Series IIC-Chemistry. 2001;4(2):85-89
  58. 58. Robert A, Benoit-Vical F, Claparols C, Meunier B. The antimalarial drug artemisinin alkylates heme in infected mice. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(38):13676-13680
  59. 59. Loup C, Lelièvre J, Benoit-Vical F, Meunier B. Trioxaquines and hemeartemisinin adducts inhibit the in vitro formation of hemozoin better than chloroquine. Antimicrobial Agents and Chemotherapy. 2007;51(10):3768-3770
  60. 60. Ooko E et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine. 2015;22:1045-1054
  61. 61. Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: Their growing importance in medicine. Trends in Pharmacological Sciences. 2008;29(10):520-527
  62. 62. Tilley L, Straimer J, Gnadig NF, Ralph SA, Fidock DA. Artemisinin action and resistance in plasmodium falciparum. Trends in Parasitology. 2016;32:682-696
  63. 63. Hassett MR, Roepe PD. Origin and spread of evolving artemisinin-resistant plasmodium falciparum malarial parasites in Southeast Asia. The American Journal of Tropical Medicine and Hygiene. 2019;101:1204-1211
  64. 64. Xu Q, Duan Y-Y, Pan M, Jin Q-W, Tao J-P, Huang S-Y. In vitro evaluation reveals effect and mechanism of artemether against toxoplasma Gondii. Metabolites. 2023;13:476
  65. 65. Hua L, Liang S, Zhou Y, Wu X, Cai H, Liu Z, et al. Artemisinin-derived artemisitene blocks ROS-mediated NLRP3 inflammasome and alleviates ulcerative colitis. International Immunopharmacology. 2022;113:109431
  66. 66. Huang Y, Yang Y, Liu G, Xu M. New clinical application prospects of artemisinin and its derivatives: A scoping review. Infectious Diseases of Poverty. 2023;12:115
  67. 67. Fitch CD, Chevli R, Kanjananggulpan P, Dutta P, Chevli K, Chou AC. Intracellular ferriprotoporphyrin IX is a lytic agent. Blood. 1983;62(6):1165-1168
  68. 68. Ba Q et al. Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1. PLoS One. 2012;7:e42703
  69. 69. Clark M, Fisher NC, Kasthuri R, Cerami Hand C. Parasite maturation and host serum iron influence the labile iron pool of erythrocyte stage plasmodium falciparum. British Journal of Haematology. 2013;161:262-269
  70. 70. Elmorshedy H, Tanner M, Bergquist RN, Sharaf S, Barakat R. Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: A randomized controlled trial. Acta Tropica. 2016;158:52-58
  71. 71. Inyang-Etoh PC, Ejezie GC, Useh MF, Inyang-Etoh EC. Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2009;103(1):38-44
  72. 72. Mnkugwe RH, Minzi O, Kinung’hi S, Kamuhabwa A, Aklillu E. Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial. PLoS Neglected Tropical Diseases. 2020;14(9):1-18
  73. 73. Nagamune K. Artemisinin induces calcium-dependent protein secretion in the protozoan parasite Toxoplasma gondii. Eukaryotic Cell. 2007;6:2147-2156. DOI: 10.1128/EC.00262-07
  74. 74. Nagamune K. Artemisinin-resistant mutants of toxoplasma gondii have altered calcium homeostasis. Antimicrobial Agents and Chemotherapy. 2007;51:3816-3823. DOI: 10.1128/AAC.00582-07
  75. 75. Vial HJ, Gorenflot A. Chemotherapy against babesiosis. Veterinary Parasitology. 2006;138:147-160. DOI: 10.1016/j.vetpar.2006.01.048
  76. 76. Efferth T. The anti-malarial artesunate is also active against cancer. International Journal of Oncology. 2001;18:767-773. DOI: 10.3892/ijo.18.4.767
  77. 77. Kelter G. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS One. 2007;2:e798. DOI: 10.1371/journal.pone.0000798
  78. 78. Chen HH. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemotherapy and Pharmacology. 2004;53:423-432. DOI: 10.1007/s00280-003-0751-4
  79. 79. Chen HH. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology. 2004;71:1-9. DOI: 10.1159/000076256
  80. 80. Wartenberg M. The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Laboratory Investigation. 2003;83:1647-1655. DOI: 10.1097/01.lab.0000098424.38003.ff
  81. 81. Jiang YY, Shui JC, Zhang BX, Chin JW, Yue RS. The potential roles of artemisinin and its derivatives in the treatment of type 2 diabetes mellitus. Frontiers in Pharmacology. 2020;11:585487

Written By

Mohan Tiwari and Saman Pathan

Submitted: 26 February 2025 Reviewed: 07 April 2025 Published: 17 June 2025